XML 67 R42.htm IDEA: XBRL DOCUMENT v3.25.4
BASIS OF PRESENTATION AND ACCOUNTING POLICIES - Narrative (Details) - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Nov. 05, 2025
Sep. 26, 2025
Temporary Equity [Line Items]          
Deferred offering costs   $ 0   $ 10,680,000  
Loss on issuance of convertible preferred stock $ 379,619,000 0 $ 0    
Warrants issued to purchase common stock (in shares)         2,552,467
Aggregate grant date fair value, warrants         $ 67,236,000
Research and development [1] $ 259,892,000 $ 206,910,000 $ 138,273,000    
Product Concentration Risk | Revenue | Transferred over Time          
Temporary Equity [Line Items]          
Concentration risk, percentage 44.00% 49.00% 38.00%    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-10-01          
Temporary Equity [Line Items]          
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01          
Temporary Equity [Line Items]          
Revenue, remaining performance obligation, expected timing of satisfaction, period 12 months        
Related Party          
Temporary Equity [Line Items]          
Research and development $ 6,073,000 $ 0 $ 0    
Fair Value, Inputs, Level 1          
Temporary Equity [Line Items]          
Cash equivalents, fair value 1,550,925,000 $ 190,223,000      
GE Aerospace          
Temporary Equity [Line Items]          
Exercise price, warrants (in dollars per share)         $ 0.002
GE Aerospace | Related Party          
Temporary Equity [Line Items]          
Loss on issuance of convertible preferred stock 215,585,000        
Warrants issued to purchase common stock (in shares)         2,552,467
GE Collaboration Agreement          
Temporary Equity [Line Items]          
Unrecognized compensation cost 61,163,000        
GE Collaboration Agreement | Related Party          
Temporary Equity [Line Items]          
Research and development 6,335,000        
Warrant expense $ 6,073,000        
Series C and Series C-1          
Temporary Equity [Line Items]          
Convertible preferred stock, purchase price (in dollars per share) $ 17.94        
Minimum | Series C and Series C-1          
Temporary Equity [Line Items]          
Convertible preferred stock, fair value range (in dollars per share) 17.94        
Maximum | Series C and Series C-1          
Temporary Equity [Line Items]          
Convertible preferred stock, fair value range (in dollars per share) $ 30.83        
[1] Includes related party amounts of $6,073, $0 and $0 (research and development) and $1,084, $(2,899) and $(1,441) (general and administrative) as of December 31, 2025, 2024 and 2023, respectively (see Note 14)